ClinicalTrials.gg
Not yet recruitingNCT07001878Updated Nov 10, 2026

Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis

A Phase 4 interventional study of Metformin in Psychosis and Cannabis Use, sponsored by Nova Scotia Health Authority. Not yet recruiting at 2 sites in Canada. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Nova Scotia Health Authority · Phase 4, Interventional, and Basic science

How we know

Updated Nov 10, 2026Now Not yet recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Psychotic Disorders by Nova Scotia Health Authority — 3 open to participants now, 3 under way, none of them phase 3. Psychotic Disorders · Nova Scotia Health Authority.

Started
2027
the only one that year
Phase 4
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Psychotic Disorders by Nova Scotia Health Authority, this one is the only one that started in 2027, is the only one in phase 4, and was the 9th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

3 of the 10 studies in Psychotic Disorders by Nova Scotia Health Authority are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Psychotic Disorders by Nova Scotia Health Authority, or all of them as a file.
02

Study summary

Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries. Recent Health Canada surveys report that 27% of 16-19-year-olds and 32% of 20-24-year-olds have used cannabis in the past 30 days, with 16-24-year-olds showing the highest rates of daily or near-daily use. Unfortunately, cannabis use has also been found to be a risk factor for the development of a psychotic disorder in emerging adults, and in those who develop psychosis and continue cannabis use, there is a significant effect on long term outcomes. This includes the severity of symptoms, risks of relapse (being hospitalized) and not reaching a level of functioning that would be expected. Lifetime experience with cannabis is greater than 80% in young adults with early phase psychosis (EPP; the first 5 years of a psychosis illness) with up to 30% of Canadian EPP patients meeting criteria for a diagnosis of cannabis use disorder (CUD) at entry to care. A recent Canadian population-based study found that cannabis use disorder associated to psychosis has risen from 3.7% pre-2018 to 10.3% at present. There has been a significant increase in Δ9-tetrahydrocannabinol (THC) levels in cannabis products available globally over the years, with popular cannabis products available start as high as 18% THC in Canada. However high potency cannabis carries a more significant risk for psychosis development, as well as higher risk for cannabis dependence and other severe mental health issues.

A major gap in the research is a specific focus on cannabis potency on brain white matter (WM) in youth and young adults, and if there are any potential treatment strategies that could be used to influence any of these cannabis WM effects. To address this, a medication called metformin, that is already used in psychosis to help with side effects of antipsychotic medications, will be used as it has also shown promise to influence WM changes in other illnesses. This project is thus focused on naturalistic cannabis potency effects on WM in emerging adults in EPP (divided into three groups; those using high potency cannabis, low potency cannabis, and minimal cannabis use) and treating them with metformin for 6 months and assessing effects on neuroimaging, cognitive and clinical variables.

The purpose of this pilot feasibility study is to inform the development/refinement of an intervention protocol, and not to test potential effects or mechanisms as the sample size will have insufficient power to perform an in-depth analysis. The results of this work will inform our research strategy development and assess feasibility of our novel methodological approach.

Participants will:

  1. Visit the clinic at baseline, 3 months (only Timeline Follow-Back Assessment administered), and 6 months post baseline to complete substance use and mental health questionnaires, and cognitive assessments
  2. Complete an MRI scan at baseline and 6 months
  3. Take Metformin every day for 6 months
Read the detailed description

Researchers will compare three groups of young adults with EPP: those using cannabis on a regular basis i) high potency (>15% THC) and ii) low potency (\<15% THC) cannabis products and iii) patients with minimal-to-no cannabis use to see if there are differences in cannabis potency effects on white matter.

This study will collect four different types of variables: demographic (things that describe the participants), clinical (things that describe how ill the individuals are), substance use (things that measure how much or how reliant participants are on recreational substances), and neuropsychological (things that measure cognitive functioning such as attention, memory, verbal learning, and executive functioning).

Baseline demographics will include age, sex, gender and ethnicity. The Timeline Followback (TLFB) method will be used to collect detailed information about current cannabis use, which includes quantity, frequency, and potency (e.g., THC %, THC/CBD). Potency data will be self-report, verified whenever possible through the use of the Nova Scotia Liquor Corporation product website and other websites used for product purchase. Cannabis quantity and frequency will be assisted by visual aids. The TLFB has been validated for use among those with schizophrenia-spectrum disorders. The World Health Organization - Alcohol, Smoking, and Substance Involvement Screening Test (WHO-ASSIST) will be used to collect non-cannabis substance use data and the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) will be used to measure problematic cannabis use. Overall psychosis symptoms will be measured by the Clinical Global Impression scale, for both severity and improvement (CGI-S, CGI-I). Cognitive data will be collected, focusing on tasks that are known to be affected by cannabis use (including high potency product). These include verbal learning and memory (California Verbal Learning Test-3; CVLT-3) and executive functioning (Trail Making Test B; TMT-B). In addition, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) will be used which includes domains of immediate memory, language, attention, and delayed memory.

Neuroimaging: Subjects will undergo a Magnetic Resonance Imaging (MRI) scan collecting T1-weighted structural, diffusion-weighted scans and magnetic resonance spectroscopy data at baseline and 6 months post baseline.

Interim and final assessments: The TLFB will be completed 3 months post baseline. At 6-months post baseline, all the above measures and imaging will be repeated (study end).

03

Conditions studied

  • Psychosis
  • Cannabis Use

Browse trials for

Keywords

  • cannabis
  • metformin
  • early phase psychosis
  • potency
04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will enroll individuals 18-25 years of age from the Nova Scotia Early Psychosis Program

Exclusion criteria

Exclusion Criteria:

  • Current stimulant use disorder
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Metformin

    All participants will receive 6 months of daily Metformin treatment and attend baseline, 3 months, and 6 months post baseline appointments.

    Drug: Metformin

Interventions

  • Metformin will be prescribed, reaching 1000mg/day (a standard dose). This will be done under the principal investigator's care and the patient's clinical team, including assessment of metformin adherence. Metformin will be prescribed for 6 months. Antipsychotic treatment will continue as per standard of care (metformin as adjunct therapy), as well as routine follow up.

    Also known as: Glucophage, Metformin Hydrochloride

06

What researchers measure

Primary outcomes

  1. Change in cannabis use

    Cannabis Timeline Followback (TLFB) is a retrospective past 30 day calendar method used to collect detailed information about current cannabis use, which includes quantity, method of use (e.g. dried cannabis smoked, concentrate vaped, edibles, etc.), frequency, strain, and potency (e.g., THC %, THC/CBD).

    Time frame: Baseline, 3 months, 6 months

  2. Treatment adherence

    The difference between the number of participants who completed 6 months of Metformin treatment compared to those who ceased using medication prior to study end at 6 months.

    Time frame: Baseline to 6 months

  3. Change in white matter microstructure

    Changes from baseline to study end at 6 months in study completers using Orientation dispersion index values from Neurite orientation dispersion and density imaging (NODDI).

    Time frame: Baseline to 6 Months

  4. Change in glial cell marker

    Measurement of glial cell marker neurochemical in the dorsomedial prefrontal region of brain Myo-inositol level changes from baseline to study end at 6 months for study completers using Magnetic resonance spectroscopy (MRS).

    Time frame: Baseline to 6 months

  5. Recruitment success

    The difference between the number of patients approached about the opportunity to participate and the total number of participants enrolled in the study for each study cohort.

    Time frame: Baseline

Secondary outcomes

  1. Change in white matter to grey matter ratio

    Changes from baseline in percent whole brain gray and white matter at 6 months assessed with MPRAGE imaging.

    Time frame: Baseline to 6 months

  2. Change in inflammatory neurochemicals

    Measurement of inflammatory neurochemical changes in the dorsomedial prefrontal region of brain by measurement of total choline level changes in dorsomedial prefrontal region of the brain from baseline to 6 months using Magnetic resonance spectroscopy (MRS).

    Time frame: Baseline to 6 months

  3. Change in overall substance use

    The WHO Alcohol, Smoking, and Substance Involvement Screening Test (WHO-ASSIST) will measure substance use risk scores to account for problematic use other than cannabis use from baseline to 6 months. Scores range from 0-39 for each substance with higher scores indicating more severe risk associated with use.

    Time frame: Baseline to 6 months

  4. Changes in problematic cannabis use

    Cannabis Use Disorder Identification Test - Revised (CUDIT-R) will be used to measure problematic cannabis use scores from baseline to 6 months on a scale of 0-32 with higher scores indicating more problematic use.

    Time frame: Baseline to 6 months

  5. Change in severity of illness

    Clinical Global Impression Scale - Severity (CGI-S) at baseline and then the complementary scale for follow-up the Clinical Global Impression Scale - Improvement (CGI-I) will measure changes from baseline in participants overall illness severity at 6 months, The CGI-S, a 7-point clinician rated Likert scale that measures individuals' overall illness severity relative those who the clinician has experienced with the same diagnosis (ranging from 1 = Normal, not at all ill to 7 = Extremely ill). The CGI-I is based on the CGI-S rating and is a 7-point clinician rated Likert scale ranging from 1 = Very much improved to 7 = Very much worse.

    Time frame: Baseline to 6 months

  6. Changes in verbal learning

    The California Verbal Learning Test - Third Edition (CVLT3) will be used to measure changes in verbal learning index scores from baseline to 6 months. The CVLT3 measures episodic verbal learning including verbal learning, immediate memory, and delayed memory. The CVLT3 yields three index scores of overall verbal learning and memory performance using a mean of 100 and a standard deviation (SD) of 15 points. The scores range from 40-160, which is 4 SDs below and above the mean.

    Time frame: Baseline to 6 months

  7. Changes in executive functioning

    Trail Making Test B (TMT-B) will be used to measure changes in recorded time taken to complete the task from baseline to 6 months. The assessment requires participant to draw a continuous line between circles containing letters and numbers in the correct ascending sequence (i.e., 1-A-2-B-3-C, etc.). Recorded test time more than 180 seconds indicates deficits in executive functioning.

    Time frame: Baseline to 6 months

  8. Changes in overall cognitive functioning

    Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) will be used to measure changes in global cognition from baseline to 6 months. The RBANS is a comprehensive neuropsychological battery for the evaluation of global cognition and has been validated in subjects with schizophrenia. It includes measures of immediate and delayed memory, attention, visuospatial construction, and language. Scores range from 0 to 160 with 100 representing the population average. Higher scores represent better cognition.

    Time frame: Baseline to 6 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to ethical and privacy considerations outlined by the Nova Scotia Health Authority. Data sharing was not a requirement of the study's funding, and given the small sample size, there is a heightened risk of re-identification of participants. To protect participant confidentiality and adhere to institutional ethics guidelines, data will remain securely stored and will not be made available to external parties.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Sep 2027, 7 months later.

Of 45 non-industry phase 4 interventional studies under Psychotic Disorders, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 71. This study's planned 7 months is below that.

Counting every sponsor, half of 51 studies reached it within 58 months; a quarter within 32 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Mar 2025 → Feb 2027, primary completion Aug 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Jun 3, 2025
StartEst.
Feb 1, 2027was Mar 2025
Primary completionEst.
Sep 30, 2027was Aug 2026
CompletionEst.
Dec 1, 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Not yet recruiting
changed Nov 10, 2026
Start date
Mar 18, 2025→Feb 1, 2027
Nov 10, 2026
Primary completion
Aug 31, 2026→Sep 30, 2027
Nov 10, 2026
Study completion
Dec 1, 2026→Dec 1, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Not yet recruiting
    Start date Mar 18, 2025→Feb 1, 2027
    Primary completion Aug 31, 2026→Sep 30, 2027
    Study completion Dec 1, 2026→Dec 1, 2027
    + 1 other change: site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07001878
Collaborators
Dalhousie University
Responsible party
Phil Tibbo (Principal Investigator, Nova Scotia Health Authority) — Principal investigator
First posted
Jun 3, 2025
Start date
Feb 1, 2027 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Rachel Church, MSc.OT
Contact
rachel.church@nshealth.ca
902-473-7474
Candice E Crocker, PhD
Contact
candice.crocker@nshealth.ca
902-473-3755
Philip G Tibbo, MD
principal investigator · Nova Scotia Health Authority

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion